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bone formation by inhibiting osteoblast proliferation. This bone deterioration leads to osteoporosis. When
considering therapy for prevention of fractures in glucocorticoid-induced osteoporosis (GIO), teriparatide
(recombinant human parathyroid hormone 1-34) is an anabolic agent that can be used to improve bone
mineral density (BMD) and prevent fractures. Due to bone deterioration caused by glucocorticoid therapy,
prevention of bone fractures has significant importance. While there are several choices for therapy for
prevention of GIO, the anabolic agent teriparatide could show a more significant improvement of BMD and of
preventing fractures resulting from GIO. The purpose of this systematic review of the literature is to evaluate
the efficacy of teriparatide in prevention of fractures that can result from glucocorticoid therapy.
Methods: An extensive literature search was conducted using Medline-OVID, CINAHL, Evidence Based
Medicine Reviews Multifile, and Web of Science using the search terms: teriparatide, osteoporosis, fractures,
and glucocorticoids. The reference sections of each of these articles were further searched for additional
relevant sources. Articles were screened and evaluated for relevance using GRADE.
Results: Two studies met inclusion criteria for this systematic review that included two randomized control
trials. These studies demonstrated that patients who were on teriparatide had increased BMD. Both studies
also measured fracture rates and showed a decrease favoring teriparatide.
Conclusion: There is sufficient evidence to recommend teriparatide as a therapeutic option for reversing the
effects of glucocorticoid-induced osteoporosis by improving bone mineral density and preventing the
occurrence of fractures, although there may still remain a question of safety that would warrant continued
research.
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Abstract   
 
Background: Glucocorticoids have a wide-range of beneficial effects for treating inflammatory, 
allergic, and immunologic conditions. However, glucocorticoid therapy can lead to increased 
bone resorption and reduced bone formation by inhibiting osteoblast proliferation. This bone 
deterioration leads to osteoporosis. When considering therapy for prevention of fractures in 
glucocorticoid-induced osteoporosis (GIO), teriparatide (recombinant human parathyroid 
hormone 1-34) is an anabolic agent that can be used to improve bone mineral density (BMD) and 
prevent fractures. Due to bone deterioration caused by glucocorticoid therapy, prevention of bone 
fractures has significant importance. While there are several choices for therapy for prevention of 
GIO, the anabolic agent teriparatide could show a more significant improvement of BMD and of 
preventing fractures resulting from GIO. The purpose of this systematic review of the literature is 
to evaluate the efficacy of teriparatide in prevention of fractures that can result from 
glucocorticoid therapy.  
 
Methods: An extensive literature search was conducted using Medline-OVID, CINAHL, 
Evidence Based Medicine Reviews Multifile, and Web of Science using the search terms: 
teriparatide, osteoporosis, fractures, and glucocorticoids. The reference sections of each of these 
articles were further searched for additional relevant sources. Articles were screened and 
evaluated for relevance using GRADE.  
 
Results: Two studies met inclusion criteria for this systematic review that included two 
randomized control trials. These studies demonstrated that patients who were on teriparatide had 
increased BMD. Both studies also measured fracture rates and showed a decrease favoring 
teriparatide.    
 
Conclusion: There is sufficient evidence to recommend teriparatide as a therapeutic option for 
reversing the effects of glucocorticoid-induced osteoporosis by improving bone mineral density 
and preventing the occurrence of fractures, although there may still remain a question of safety 
that would warrant continued research.  
 
Keywords: teriparatide, fractures, osteoporosis, and glucocorticoids. 
 
 
 
5 
 
Acknowledgements 
 
 
 To my parents and extended family members, I can’t thank you enough for your support 
and encouragement over the years.  Though my path can never be what I intend for it, the way it 
has evolved has opened me to discovery beyond what I could imagine.  To those classmates who 
have been closest and most supportive, thanks for your advice and willingness to share in this 
educational adventure.  The wonderful faculty at Pacific University’s PA program has been 
invaluable, as you have dedicated yourselves to us reaching our highest educational potential and 
have cared about our personal well-being throughout the process.  
6 
 
List of Tables  
 
Table 1:       GRADE Quality of Assessment and Summary of Findings 
 
List of Figures 
 
 
Figure 1:     Pathophysiology of Glucocorticoid-Induced Osteoporosis Leading to Fractures 
 
List of Abbreviations 
 
GIO   Glucocorticoid-Induced Osteoporosis 
PTH   Parathyroid Hormone 
BMD   Bone Mineral Density 
hPTH 1-34  Human Parathyroid Hormone 1-34 
QCT   Quantitative Computed Tomography  
DXA   Dual energy X-ray Absorptiometry  
GC   Glucocorticoids 
 
 
 
 
 
 
7 
 
Effectiveness of Teriparatide Therapy for Prevention of Fractures in 
Glucocorticoid-Induced Osteoporosis 
 
 
BACKGROUND 
 
 Glucocorticoids (GC) have a wide-range of beneficial effects for treating 
chronic inflammatory conditions such as asthma, rheumatoid arthritis, and systemic lupus 
erythematosus. They are also used for allergic, immunologic, and malignant conditions. 
While their benefits are extensive, chronic GC use can lead to increased bone resorption 
by inhibiting osteoblast proliferation causing reduced bone formation, as well as lowering 
intestinal calcium absorption, and renal calcium excretion.1 This bone deterioration leads 
to osteoporosis. Because of this side effect, patients on glucocorticoid therapy have 
increased risk of fractures2 (See Figure 1). Glucocorticoid-induced osteoporosis (GIO) 
can be rapid and is most pronounced within the first three months of use, which is 
followed by slower, steady bone loss with ongoing use.1 Patients on glucocorticoids can 
have changes in their bone mineral density (BMD) increasing their risk of fracture.3 The 
most common areas of fractures and those which occur the earliest, are the lumbar 
vertebrae. Other fracture areas caused by GIO include the hips and femoral neck.1 The 
World Health Organization defines a diagnosis of osteoporosis when BMD is 2.5 or more 
standard deviations below normal peak bone mass (a T-Score of -2.5 or less being 
osteoporotic, and a T-Score of -1 or greater being normal). Prevention of GIO and 
fractures that result from the condition, is aimed at reversing the effects of the 
glucocorticoids, either by decreasing the dose of exogenous glucocorticoid, using 
supplements of vitamin D and calcium, by weight-bearing exercise, or by pharmacologic 
8 
 
intervention to minimize or reverse bone loss.4 Pharmacologic therapy includes 
calcitonin, oral bisphosphonates, IV bisphosphonates, estrogen, selective estrogen-
receptor modulators, and anabolic skeletal agents. Antiresorptive therapies, which are the 
bisphosphonates including alendronate and risendronate, are labeled as the first line uses 
(along with calcium and vitamin D supplements) for treating GIO. However, the 
bisphosphonates only maintain BMD.5 It has been suggested that combination 
glucocorticoid therapy in osteoporotic patients with long term treatment of antiresorptive 
medications, may have an increased risk of atypical supratrochanteric and diaphyseal 
fractures.5 
Teriparatide [recombinant human PTH 1-34 (Forteo, Eli Lilly and Co., 
Indianapolis, IN)] is an anabolic agent approved for use in the United States that can be 
used to improve BMD and prevent fractures.5 It is a bone anabolic agent used for the 
treatment of osteoporosis in men and women with high risk of fractures. Teriparatide may 
be a more rational treatment for GIO because of its ability to increase osteoblast function, 
decrease osteoblast and osteocyte apoptosis, and increases the differentiation of bone 
lining cells and preosteoblasts into osteoblasts, which improves the microarchitecture of 
bone and increases its strength.6 A meta-analysis of randomized control trials by Han et 
al7 determined teriparatide to substantially reduce the risk of fragility fracture in 
postmenopausal women with a 70% reduction in vertebral fracture and a 38% reduction 
in non-vertebral fracture. An observational study8 conducted over a 36 month period 
found that post-menopausal women with GIO who were put on teriparatide therapy for 
18 months and followed an additional 18 months once teriparatide was discontinued, had 
an immediate reduction of clinical fractures during treatment and continued to see a 
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reduced incidence of fracture once treatment was stopped.  Another study9 found 
teriparatide to offer more protection against fractures in women suffering from 
postmenopausal osteoporosis. Teriparatide is generally well-tolerated and rarely has side 
effects. The most common side effects it has includes injection-site pain and swelling 
(<3.3% of patients), nausea (8.5%), headaches (7.5%), leg cramps (2.6%), and dizziness 
(8%).10 There were no significant safety concerns mentioned by Han et al7 in their recent 
meta-analysis. Though, teriparatide has a limited use to 2 years because of the concern 
for human safety due to previous animal studies showing osteosarcoma related to 
teriparatide use beyond 3 years.11 Teriparatide is currently offered as a second-line 
treatment for the prevention of GIO due to its cost. Another drawback is its route of 
administration as a subcutaneous injection.3 
Because of the bone deterioration caused by glucocorticoid therapy prevention of 
bone fractures has significant importance. The bisphosphonates and other osteoporosis 
therapies don’t specifically target this mechanism. This leaves teriparatide as a more 
appealing approach.6 Teriparatide could have more significant therapeutic improvement 
of BMD and prevention of fractures resulting from long term glucocorticoid use, because 
of its mechanism of action. The purpose of this systematic review of the literature is to 
evaluate the efficacy of teriparatide in the prevention of fractures that can result from GC 
therapy.  
 
METHODS 
 
    An extensive literature search was conducted using Medline-OVID, CINAHL, 
Evidence Based Medicine Reviews Multifile, and Web of Science using the search terms: 
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teriparatide, osteoporosis, fractures, and glucocorticoids. The search was narrowed to 
include English-language articles, human studies, and primary data. The reference 
sections of each of these articles were further searched for additional relevant sources.   
Inclusion criteria was based on adults who had a diagnosis of osteoporosis, were on 
glucocorticoid therapy, had a history of glucocorticoid-induced osteoporosis, had 
experienced fractures caused by glucocorticoid therapy, and were being treated with 
teriparatide therapy. Studies were excluded from this systematic review if they involved 
current treatment for another experimental drug or procedure. They were also excluded if 
they studied patients who were currently on or had been recently treated with a 
bisphosphonate.  Articles were screened and evaluated for relevance using Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE).12  
RESULTS 
 
Using the search terms described in the previous section, the initial search yielded 
18 articles for review.  After screening relevant articles for human-studies and primary 
data, two articles met inclusion criteria. These two articles included a randomized, 
double-blind, control trial,13 and a randomized, control trial14 (See Table 1).  
 
Saag et al 
 This randomized, double-blind, double-dummy, active comparator-controlled 
trial13 occurred over a period of 36 months in 13 countries at 76 centers comparing 
teriparatide with the antiresorptive drug alendronate (a Bisphoshonate) for treating 
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glucorticoid-induced osteoporosis (GIO).  There were 428 participants enrolled with 
osteoporosis (ages 22 to 89 years) and who had received glucocorticoids for at least 3 
months (prednisone equivalent, 5mg daily or more). The study had three phases starting 
with a screening phase for 1.5 months, an 18 month primary phase, and a further 18 
month continuation phase.  The investigators and participants remained blinded 
throughout the course of the treatment for 36 months.  The primary objective of the study 
was to investigate the change in BMD from baseline to 18 months between the 
teriparatide treatment group and the alendronate treatment group.  Secondary objectives 
for the continuation to 36 months included evaluation of vertebral and nonvertebral 
fracture incidence.13 
  Participants were eligible for enrollment if they were ambulatory men or women, 
at least 21 years of age, and they had taken prednisone or an equivalent at a dosage of 
greater than or equal to 5 mg per day for at least 3 months prior to screening.  Each 
participant gave informed written consent, and an institutional review committee 
approved the protocol. The study was conducted under appropriate clinical guidelines in 
accordance with the Declaration of Helsinki and the Guidelines of Good Clinical 
Practice. The participants were also required to have a BMD T score of < -2 or of < -1 
plus a low trauma or atraumatic fracture, for their lumbar spine, femoral neck, or total 
hip. Participants were randomly assigned to receive 20 µg of injectable teriparatide per 
day plus an oral placebo or 10 mg of oral alendronate per day plus an injectable placebo.  
Supplements of calcium and vitamin D were provided at dosages of 1,000 mg/day and 
800 IU/day, respectively.  The participants kept a daily diary of their glucocorticoid use.  
Baseline glucocorticoid use was determined by the duration and dosage of only the 
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glucocorticoids the participant was taking at study entry.  Each visit had an average 
glucocorticoid dose determined by averaging the prednisone equivalent dose taken since 
the previous visit.13   
     Bone mineral density was measured using dual x-ray absorptiometry using 
Hologic (Hologic, Bedford, MA) or Lunar (General Electric Medical Systems, Madison, 
WI) densitometers.  Bio-Imaging Technologies (Newport, PA) performed reading of the 
BMD scans, quality assurance, cross calibration adjustment, and data processing.  
Lumbar vertebrae that became fractured during the trial were excluded from the 
calculation of baseline and postbaseline lumbar spine BMD.13  
 There were also spinal radiographs obtained at baseline, at 18 months, and at 36 
months.  If there were symptoms suggestive of clinical vertebral fracture or other fracture 
symptoms experienced by participants, they were evaluated with spinal radiographs and 
radiographs of the other symptomatic areas.  Regarding spinal compression fractures, 
each vertebra was graded for compression deformity by visual semiquantitative method 
using a Bio-Imaging Technologies radiologist who was blinded with regard to the 
treatment, but not to the sequence of radiographs.  If there was an incident vertebral 
fracture discovered that was not fractured at baseline, it was subsequently graded as 
deformed.  Also, if there were nonvertebral fractures, the radiologist was blinded to the 
treatment.  This type of fracture was defined as a fracture associated with trauma 
equivalent to a fall from standing height or less, as assessed by the investigator.13 
The analysis of the randomized subjects treated for BMD was conducted by 
means of a group comparison between baseline and end point. This involved using the 
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last observation carried forward method, which is defined at 36 months or at last 
postbaseline measurement with stratification variables as covariates using using Analysis 
of Variance (ANOVA). By using a pre-defined gate-keeping strategy, overall Type I 
error was controlled at an alpha level of 0.05 for determining the earliest time at which 
the increase in BMD differed significantly between groups.  If the 36-month comparison 
was significant at the 5% level then the 24-month comparison was tested, and this pattern 
was continued. This approach ensured that overall Type I error was not increased above 
the 0.05 level by testing at multiple time points.  Testing of the remaining secondary 
outcomes, did not use adjustment for multiple comparisons.13 
A within-treatment group post hoc analysis was used to determine whether 
percentage change in BMD was significantly different at successive time points.  This 
was done using the mixed model with contrast.  The covariates that were included were 
treatment, stratification variables, baseline lumbar spine BMD, time of appointment, and 
interaction between visit and treatment.  There were additional subgroup analyses 
performed using ANOVA evaluating glucocorticoid dosage at baseline and 36 months, 
other musculoskeletal disease, respiratory disorders, and underlying conditions requiring 
glucocorticoids.13 
 Out of the 428 randomized subjects who received treatment, 150 (70%) of the 
subjects receiving teriparatide entered the 18 month continuation phase. Of those 
receiving alendronate 144 (67%) did so. Of the 150 treated with teriparatide, 123 (57%) 
completed the entire trial. Of the alendronate group, 118 (55%) participants continued to 
the completion.  During these two phases, the most common reasons for discontinuation 
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in the study were subject decision and unspecified adverse event in both groups, with no 
significant difference between the treatment groups.  There were more teriparatide 
subjects that discontinued due to physician decision and while more alendronate subjects 
were lost to follow-up.13 
 The differences in mean percentage in lumbar spine, total hip, and femoral neck 
BMD were greater in the teriparatide group than the alendronate group over the course of 
the trial from each time point until the end point.  When comparing the teriparatide group 
to the alendronate group with regard to bone mineral density at 36 months, the mean 
percent increases from baseline were 11.0% versus 5.3%, respectively, for lumbar spine 
BMD (P < 0.001), 5.2% versus 2.7%, respectively, for total hip BMD (P < 0.001), and 
6.3% versus 3.4% , respectively, for femoral neck BMD (P < 0.001).  In the teriparatide 
group, the mean percent changes in BMD were significantly greater between the 
successive time points from 3 through 36 months at the lumbar spine, between 12 and 18 
months and between 18 and 24 months at the total hip, and between 24 and 36 months at 
the femoral neck. In the alendronate group, the mean percent changes in BMD were 
significantly greater between 3 and 6 months, 6 and 12 months, and 18 and 24 months at 
the lumbar spine, between 12 and 18 months at the total hip, and between 12 and 18 
months and 24 and 36 months at the femoral neck. The mean percent increases in BMD 
for both treatment groups were significant compared to baseline at each interval (P < 
0.001 for teriparatide and P < 0.002 for alendronate, at all sites).13  
 There were no effects on BMD from underlying diseases that required 
glucocorticoid therapy.  This was the same with regard to percentage change in lumbar 
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spine BMD from baseline to end point in both treatment groups.  There was no 
significant difference across 4 underlying disease subgroups or across the 3 
glucocorticoid dosage ranges.13  
     With regards to incidence of vertebral and nonvertebral fractures, there were a 
total of 3 (1.7%) of 173 subjects receiving teriparatide compared with 13 (7.7%) of 169 
subjects receiving alendronate had 1 new radiographic vertebral fracture over 36 months 
(P = 0.007). This had a relative risk of 22% and a number needed to treat of 17 (See 
Table 1). Most of the vertebral fractures occurred during the first 18 months (1 within the 
teriparatide group and 10 with the alendronate group). There were no significant 
differences between groups in the number of subjects with new nonvertebral fractures or 
with new nonvertebral fragility fractures.13 
     The authors admitted to some limitations including the 44% dropout rate at 36 
months, but failed to address the specific reasons. They concluded that teriparatide was 
superior to alendronate in both areas and that it should be considered a viable option for 
treatment GIO.13 
Lane et al 
 In this randomized, control study14 the authors conducted a 12 month clinical trial 
of human parathyroid hormone 1-34 (hPTH 1-34) in postmenopausal women with 
osteoporosis who were taking corticosteroids and hormone replacement therapy.  Study 
subjects were selected as postmenopausal women between 50 and 82 years of age with a 
variety of chronic, noninfectious inflammatory diseases.  They were eligible for the study 
if they had osteoporosis defined by a low bone mass (less than 2.5 standard deviations 
16 
 
below mean young normal values at the lumbar spine or femoral neck), had been 
menopausal for greater than or equal to 3 years, had been taking hormone replacement 
therapy (premarin or another estrogen at an equivalent dose) for greater than or equal to 1 
year, had been treated with prednisone or an equivalent for the previous 12 months at a 
mean daily dose of 5.0 – 20.0 mg, and were expected to continue corticosteroid treatment 
for one year.  Patients were excluded if they had a secondary form of osteoporosis other 
than one from rheumatic diseases and corticosteroids, renal or hepatic dysfunction, or 
abnormalities on spinal radiographs that precluded accurate measurements of the lumbar 
spine by quantitative computed tomography (QCT) or dual energy x-ray absorptiometry 
(DXA).  The participants all gave informed consent and the study was approved by the 
Committee on Human Research of the University of California, San Francisco.14  
 Fifty-one women who were postmenopausal and currently on estrogen and 
corticosteroids (CS) were randomly assigned by a computer generated table either to 
receive hPTH 1-34 plus estrogen (n=28), or to remain on estrogen only (n=23). The 
patients were given a calcium supplement of 1,500 mg per day and 800 IU of vitamin D3 
supplement per day.  The mean daily CS dose remained the same in the groups 
throughout the 12 month study period. Patients were taught subcutaneous self-injection 
by the research nurse at the start of the study.  Placebo injections were not used.  For 12 
months hPTH 1-34 was at a dose of 25 µg (400 U) per day. Compliance was estimated by 
measuring the remaining volume in the returned medication vials at each study visit and 
ranged from 80 – 90% of the daily doses.  Patients were evaluated at 1 month and then 
for every 3 months for 1 year to monitor the safety and efficacy of the treatment.  Bone 
mass measurements of the lumbar spine by QCT were done from baseline and at 12 
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months.  Bone mass measurements using DXA of the spine, hip, and forearm were 
performed every 6 months.  Baseline DXA scans were obtained in duplicate and one 
every 6 months thereafter. The average of the baseline duplicate scan values was used in 
the analysis.  Quality assurance data was collected daily from the DXA scanner to assess 
performance.  Long-term in vivo precision error was 1.5% for the lumbar spine, 1.0% for 
the total hip region, 2.0% for the greater trochanter, 1.0% for the proximal or mid-
forearm, and 3.0% for the distal 1/3 of the radius.14   
 Radiographs of the thoracolumbar spine were done annually by a standard 
technique to assess fractures at baseline and those during the course of the study. A new 
vertebral fracture was defined as a decrease of 20% and at least 4 mm in any vertebral 
height from baseline radiograph to that taken at completion of the study. Each fracture 
was confirmed by a repeat digitization of the involved vertebrae.14   
     Statistical analysis was performed looking at baseline differences between the 
groups. They were tested for significance with Student’s t test for normally distributed 
variables.  Differences between the hPTH 1-34 plus estrogen group and estrogen-only 
groups during the course of the treatment were analyzed by repeated-measures using 
ANOVA.  Tukey’s method was used for post-hoc analysis.14 
 The BMD of the lumbar spine measured by QCT and DXA increased 
significantly in the parathyroid plus estrogen group (P < 0.001) and remained the same in 
the estrogen only group.  The mean differences between the treatment groups at 12 
months (calculated by analysis of covariance) were 33.5% for the lumbar spine by QCT 
(P < 0.001) and 9.8% by DXA (P < 0.001).  Compared to the spinal bone mass changes 
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with the hPTH treatment, there were only slight increases of 2.0% in the total hip, 2.9% 
in the femoral neck, and 1.3% in the greater trochanter.  There was no significant decline 
in BMD at the spine or at the hip in the estrogen-only group.  Bone mineral density of the 
forearm decreased about 1.0% in both groups during the 12 month study.  There were no 
significant differences found between the groups with respect to BMD of the total hip, 
femoral neck, greater trochanter, or 1/3 distal radius at 6 and 12 months.14  
 No patients in the hPTH group (0/26) suffered a new vertebral fracture and one 
patient in the estrogen-only group (1/18) had evidence of a new vertebral fracture at the 
12 month visit. This has a relative risk of 47% with a number needed to treat of 12 (See 
Table 1). During the treatment period, there were two patients in the hPTH plus estrogen 
group that had nonvertebral fractures (radius and pelvis) as did two patients in the 
estrogen only group (sacrum and rib).14    
 The authors felt that postmenopausal women with corticosteroid induced 
osteoporosis could benefit from daily subcutaneous injection of hPTH 1-34.  No study 
limitations were addressed.14  
DISCUSSION 
 
These two studies13,14 demonstrate that teriparatide is an effective therapeutic option for 
patients with glucocorticoid-induced osteoporosis at high risk for fractures.  Glucocorticoid 
therapy is beneficial for the treatment of chronic inflammatory, allergic, and 
inflammatory conditions. However, chronic use of GC therapy can lead to deterioration 
of the matrix in bone. Osteoporosis arises as a result of the side effects of long term 
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glucocorticoid use, which can be debilitating due to a reduction in bone mineral density, 
leading to increased risk of fractures. Because of the effects of long term glucocorticoid 
use, therapy is aimed at reversing the effects that result from GIO. Teriparatide has 
beneficial effects of reversing the cause of GIO, however, it is often a second-line agent because 
of its cost and route of administration being an injection, and its effect can vanish after a few 
month or year once therapy is discontinued.3 It is also limited on its use to 2 years because of the 
concern for human safety due to previous animal studies showing osteosarcoma related to 
teriparatide use beyond 3 years.15   
Teriparatide is a more beneficial alternative to the bisphosphonates because of having a 
considerably improved BMD and lower incidence of fractures. Due to teriparatide’s anabolic 
activity, bone health in patients with GIO can be stabilized to avoid deterioration, prevent 
fractures, and to improve a GIO patient’s quality of life. A meta-analysis of randomized control 
trials by Han et al7 determined teriparatide to substantially reduce the risk of fragility fracture in 
postmenopausal women with a 70% reduction in vertebral fracture and a 38% reduction in non-
vertebral fracture. The EFOS study8 showed that teriparatide has an immediate and long 
lasting effect, reducing the occurrence of clinical fractures both during treatment and 
after treatment.  Teriparatide has also been found to offer more protection against fractures 
significantly in women suffering from postmenopausal osteoporosis.9 Based on the 
pathophysiology of bone degeneration caused by GIO, it has been recommended that 
pharmacologic agents that stimulate bone formation and accelerate remodeling (most 
significantly in trabecular bone of the lumbar spine), such as teriparatide, may be the 
more appropriate treatment option over antiresorptive agents for patient with GIO at high 
risk for fractures,16,17 which was also a conclusion by Lane et al.14 Because of its efficacy 
over bisphosphonates in improved bone mineral density and reduced fracture rates, teriparatide 
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should be considered as a first line option for the treatment of glucocorticoid-induced 
osteoporosis. 
After evaluation of a randomized, double blind, control trial of subjects receiving 
teriparatide in comparison to subjects receiving alendronate, there were significantly 
greater increases in spine and hip BMD, and fewer new vertebral fractures, in those 
receiving teriparatide over a 36 month time period.13 In comparing BMD changes, there 
was an increase of 11% versus 5.3% for L-Spine, 5.2% versus 2.7% for total hip, and 
6.3% versus 3.4% for femoral neck (P < 0.001 for all).13 This shows considerable benefit 
of teriparatide as its BMD improvement is nearly double to  that of alendronate in 
patients with GIO. The trial also shows efficacy of reduced incidence of fracture in those 
receiving teriparatide.  For example, in the teriparatide group there were 3 new 
radiographic fractures out of 173 participants, versus 13 out of 169 participants in the 
alendronate group over a 36 month period.13 The relative risk for this was 22% and the 
number needed to treat was 17 (See Table 1). Fracture incidence is significantly lower in 
the teriparatide group, suggesting that its effects could be therapeutically superior to 
alendronate in preventing the occurrence of fractures. The authors also avoided 
inaccuracies using approaches such as daily diaries made by the participants of their 
glucocorticoid use and compliance with usage of the drugs being compared.13 It was 
noteworthy that mean percent changes in BMD were significantly highest and changed 
the earliest in the lumbar spine region (at 3 mos.), since this is the area of bone that can 
have the first signs of GIO and most likely to experience factures.1 There was 
improvement in the total hip (18 mos.) and femoral neck (24 mos.) much later than the 
lumbar spine, which is significant since the fracture occurrence in this study was highest 
21 
 
in the first 6 months.  Therefore, clinical application of teriparatide can help avoid spinal 
fractures faster since it showed improvement in BMD within the first 3 months.  Patients 
that are at high risk of deterioration and fracture associated with long term glucocorticoid 
use, can have significantly greater benefit in improved BMD in the spine, hip, and 
femoral neck, as well as a lower likelihood of vertebral fracture, if they are placed on 
teriparatide over alendronate.  
Lane et al14 evaluated how postmenopausal women taking stable, low doses of 
chronic glucocorticoids and estrogen supplementation could have changes in bone 
mineral density when placed on hPTH 1-34. The treatment with hPTH 1-34 in these 
subjects showed a dramatic increase of bone mass in spinal trabecular bone and integral 
bone, as well as minimal increases of bone mass in the bones of the hip and forearm.14  
This is again, suggestive that teriparatide helps the bones that are most affected by GIO, 
which was also evident in the work performed by Saag et al.13 None of the patients in the 
hPTH group suffered a new vertebral fracture, while there was one in the estrogen-only 
group over the 12 month study period.  Between the two groups, there were four non-
vertebral fractures over the 12 month period.  This shows a relative risk of 47% with a 
number needed to treat of 12 (See Table 1). There was also no evidence of harmful or 
adverse effects from the hPTH 1-34 treatment. This improved bone mass from 
administration of hPTH 1-34 provides reasonable evidence for reversing the effects of 
GIO and preventing the occurrence of fractures. 
 While the studies13,14  of this systematic review demonstrated teriparatide to be 
effective for improving BMD and reducing fracture incidence, they each have their 
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limitations.  The randomized, double blind, control trial by Saag et al13 was of moderate 
quality with a serious limitation being from a high attrition rate of 44% at the completion 
of 36 months. The authors noted that the most common reason for study discontinuation 
were by physician decision and adverse events.13 However, they failed to describe or 
discuss the specifics of what those adverse events were that could have lead to the high 
attrition rate. This is concerning since it would be important to know what those specific 
adverse events were if it they can be attributed to safety concerns. It is possible, that the 
high attrition rate of the study subjects could have been due to the severity of underlying 
diseases associated with treatment of glucocorticoids, as well as resulting from other 
comorbid conditions. There could have been inconsistencies due to the locations of the 
study, as it spanned across 13 countries and was not limited to the United States. There 
was also a lack of precision due to a small sample size. This was the same case for the 
study by Lane et al14 which had only 28 people in the teriparatide treatment group and 20 
in the control group.  
Lane et al14 studied only female patients that were postmenopausal between the 
ages of 50-82 further limiting the applicability of the study. This study also discussed the 
use of radiographs to evaluate the presence of fractures, but was not clear on when those 
radiographs occurred. They described them as annual, but also wrote that radiographs 
were taken at 6 and 12 months. The authors of this study also had no discussion of any 
limitations they experienced or in their methodology. The evidence yielded by Lane et 
al14 was of moderate quality which was negatively affected by small sample size and had 
a serious limitation of not being blinded. 
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    These studies13,14 answer the question regarding teriparatide for the prevention of 
fractures in patients with GIO.  The study by Saag et al13 had a number needed to treat of 
17 and the study by Lane et al14 had a number needed to treat of 12.  Both studies also 
had results of improved bone mineral density in subjects with GIO who were treated with 
teriparatide. There is little doubt that teriparatide is a useful treatment option for GIO, 
even given that the quality of evidence from this systematic review has revealed 
significant limitations to the studies.   
 
CONCLUSION 
Teriparatide is well tolerated offering therapeutic efficacy of improved BMD and should 
be considered for protection against fractures resulting from glucocorticoid-induced osteoporosis. 
It has shown improvement more significantly than bisphosphonates when treating the effects of 
GIO as well as preventing the incidence of fractures. The data of teriparatide therapy overall 
make it an efficacious treatment option for GIO and other forms of osteoporosis, when compared 
to other therapies. Teriparatide therapy by daily subcutaneous injection can result in lower 
incidence of GIO effects after initiation of therapy and continues to prevent the effects of GIO 
once therapy has stopped.  When combining the quality of studies reviewed, the overall quality is 
moderate according to the GRADE criteria (See Table 1).  
It is still important to consider further research for the use of teriparatide treatment in a 
variety of causes of osteoporosis as well as the possibility of refining it to be safer for humans 
beyond 2 years. Because of the concern raised by the work of Saag et al12 of no definitive reason 
for what the adverse events were, research aimed at the safety of teripartide use for GIO and other 
forms of osteoporosis in randomized control trials would be more convincing that it is a safe 
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therapeutic option.  Further randomized control trials with a larger study population including 
men and women with GIO, or other forms of osteoporosis, looking at improved BMD and 
reduction of fracture incidence would also benefit decision making for teriparatide as a treatment 
option.  There could also be more randomized comparative studies with bisphosphonates and 
other osteoporotic medications using a larger, more diverse patient population to see how 
teriparatide’s efficacy measures up as a go to treatment option for prevention of fractures.  While 
further research could significantly benefit the understanding, effectiveness, and safety of 
teriparatide, it has proven to significantly benefit the BMD bones that are most effected by GIO 
as well as being a preventative measure for avoiding fractures that result from GIO.  
Though the cost and limited time of applicability for teriparatide treatment may steer one 
away from using teriparatide for treating GIO and other forms of osteoporosis, it has a 
mechanism of action that has proven to significantly improve BMD and prevent fractures both 
after initiation of therapy and for some time once it is discontinued.  
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aThere was a small number of patients who were studied for fracture rates (28) and an attrition rate of 44% over the 36 month time course.  
bThere was no blinding used in the study 
cBone mineral density was measured by percentage change using dual x-ray absorptiometry. 
dBone mineral density was measured by percentage change using quantitative computed tomography (QCT) or dual-energy x-ray absorptiometry (DXA).   
 
Table 1 - GRADE Evidence Profile: Teriparatide for prevention of fractures in patients with glucocorticoid-induced 
osteoporosis. 
 
Quality Assessment Summary of Findings 
 Downgrade Criteria  Number of Patients Effect 
Study Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Study 
Treatment 
(total) 
Placebo or no 
treatment 
(total) 
Relative 
Risk 
NNT 
Quality 
Importance 
Fractures 
Saag et 
al13 
 
Randomized 
Control Triala 
Serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely 
Saag et al13 
 
428 214 0.22 17 Moderate Important 
Lane et 
al14  
Randomized 
Control Trial 
 Serious 
Limitationsb 
No Serious 
indirectness 
No Serious 
imprecision  
No serious 
inconsistencies 
No bias 
likely 
Lane et al14 28  23 0.47 12 Moderate Important 
Bone Mineral Density  
Mean % 
Change in 
Treatment
Groupc,d 
Mean % 
Change in 
Treatment 
Groupc,d 
Saag et 
al13 
 
Randomized 
Control Trial 
Serious 
Limitationsa 
No Serious 
Limitations 
No Serious 
Imprecision 
No Serious 
Inconsistencies 
No Bias 
Likely 
Saag et al13 
 
428 214 
11% 5.3% 
Moderate Important 
Lane et 
al14  
Randomized 
Control Trial 
 Serious 
Limitationsb 
No Serious 
indirectness 
No Serious 
imprecision  
No serious 
inconsistencies 
No bias 
likely 
Lane et al14 28 23 N/A N/A Moderate Important 
28 
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Figure 1. Pathophysiology of Glucocorticoid-induced Osteoporosis Leading to Fractures 
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